mecamylamine has been researched along with Cognition Disorders in 9 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In smokers with schizophrenia and control smokers, overnight abstinence led to undetectable plasma nicotine levels and an increase in tobacco craving." | 3.73 | Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. ( Dudas, MM; George, TP; Jatlow, PI; Krishnan-Sarin, S; Sacco, KA; Seyal, A; Termine, A; Vessicchio, JC; Wexler, BE, 2005) |
| "Tamoxifen (TMX) is a selective estrogen receptor modulator that is used as an estrogen receptor antagonist for the treatment and prevention of breast cancer." | 2.78 | Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women. ( Albert, K; Astur, R; Dumas, J; Johnson, J; Naylor, M; Newhouse, P, 2013) |
| "Memantine was also effective in these tests and concomitant administration of subeffective doses of ZSET1446 and memantine significantly ameliorated the cognitive performance in the novel object recognition task in both mice and rats." | 1.39 | Combination effects of ZSET1446/ST101 with memantine on cognitive function and extracellular acetylcholine in the hippocampus. ( Hino, M; Takeda, K; Yamaguchi, Y, 2013) |
| "Rivastigmine (2 mg/kg) reduced cerebral edema by at least 50% (p < 0." | 1.30 | Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse. ( Chen, Y; Constantini, S; Shohami, E; Weinstock, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Newhouse, P | 1 |
| Albert, K | 1 |
| Astur, R | 1 |
| Johnson, J | 1 |
| Naylor, M | 1 |
| Dumas, J | 1 |
| Yamaguchi, Y | 1 |
| Takeda, K | 1 |
| Hino, M | 1 |
| Miyauchi, M | 1 |
| Neugebauer, NM | 1 |
| Oyamada, Y | 1 |
| Meltzer, HY | 1 |
| Sacco, KA | 2 |
| Termine, A | 2 |
| Seyal, A | 1 |
| Dudas, MM | 2 |
| Vessicchio, JC | 2 |
| Krishnan-Sarin, S | 1 |
| Jatlow, PI | 1 |
| Wexler, BE | 2 |
| George, TP | 2 |
| Seyal, AA | 1 |
| Allen, TM | 1 |
| Phillips, JM | 1 |
| Ehrlichman, RS | 1 |
| Siegel, SJ | 1 |
| Brioni, JD | 1 |
| O'Neill, AB | 1 |
| Kim, DJ | 1 |
| Buckley, MJ | 1 |
| Decker, MW | 1 |
| Arneric, SP | 1 |
| Chen, Y | 1 |
| Shohami, E | 1 |
| Constantini, S | 1 |
| Weinstock, M | 1 |
| Newhouse, PA | 1 |
| Potter, A | 1 |
| Corwin, J | 1 |
| Lenox, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Estrogen Modulation Effects on Cholinergic Function in Normal Post-Menopausal Women and Patients With Alzheimer's Disease[NCT00006399] | Phase 2 | 45 participants | Interventional | 1999-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for mecamylamine and Cognition Disorders
| Article | Year |
|---|---|
Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women.
Topics: Aged; Attention; Cholinergic Antagonists; Cognition Disorders; Estrogen Antagonists; Female; Humans; | 2013 |
Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist.
Topics: Adult; Cognition Disorders; Female; Humans; Male; Mecamylamine; Memory Disorders; Nicotinic Antagoni | 2006 |
Acute nicotinic blockade produces cognitive impairment in normal humans.
Topics: Adult; Analysis of Variance; Behavior; Cognition Disorders; Humans; Male; Mecamylamine; Memory; Neur | 1992 |
6 other studies available for mecamylamine and Cognition Disorders
| Article | Year |
|---|---|
Combination effects of ZSET1446/ST101 with memantine on cognitive function and extracellular acetylcholine in the hippocampus.
Topics: Acetylcholine; Administration, Oral; Animals; Cognition; Cognition Disorders; Dihydro-beta-Erythroid | 2013 |
Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Azetidines; Benzamides; Bridged Bicyclo Compounds; | 2016 |
Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.
Topics: Adult; Attention; Behavior, Addictive; Cognition; Cognition Disorders; Comorbidity; Female; Humans; | 2005 |
Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma.
Topics: Acetylcholine; Action Potentials; Animals; Biological Clocks; Brain; Cognition Disorders; Evoked Pot | 2007 |
Anxiolytic-like effects of the novel cholinergic channel activator ABT-418.
Topics: Administration, Oral; Animals; Anti-Anxiety Agents; Cognition Disorders; Diazepam; Isoxazoles; Male; | 1994 |
Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse.
Topics: Animals; Brain Edema; Carbamates; Cholinergic Antagonists; Cholinesterase Inhibitors; Cognition Diso | 1998 |